Nectar Lifesciences Ltd
Fundamental Score
Nectar Lifesciences Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of NECLIFE across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Strong Cash Generation (₹604.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
10 factors identified
Below-Average Return on Equity (-11.23%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-5.36%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Profit Decline Concern (-43.48%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Limited Growth History (-6.77% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Interest Coverage (-4.08x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Limited Institutional Interest (FII+DII: 0.70%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
High Share Pledging Risk (98.77%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns or margin calls.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Financial Statements
Comprehensive financial data for Nectar Lifesciences Ltd
About NECLIFE
Business Overview
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
Company Details
Key Leadership
Corporate Events
NECLIFE Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Nectar Lifesciences Ltd (NECLIFE)?
As of 29 Jan 2026, 10:32 am IST, Nectar Lifesciences Ltd (NECLIFE) is currently trading at ₹13.72. The stock has a market capitalization of ₹390.66 (Cr).
Is NECLIFE share price Overvalued or Undervalued?
NECLIFE is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Nectar Lifesciences Ltd share price?
Key factors influencing NECLIFE's price include its quarterly earnings growth (Sales Growth: -0.52%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Nectar Lifesciences Ltd a good stock for long-term investment?
Nectar Lifesciences Ltd shows a 5-year Profit Growth of N/A% and an ROE of -11.23%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.64 before investing.
How does Nectar Lifesciences Ltd compare with its industry peers?
Nectar Lifesciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare NECLIFE's P/E of 0.00x and ROE of -11.23% against the industry averages to determine its competitive standing.
What is the P/E ratio of NECLIFE and what does it mean?
NECLIFE has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is NECLIFE performing according to Bull Run's analysis?
NECLIFE has a Bull Run fundamental score of N/A/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does NECLIFE belong to?
NECLIFE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Nectar Lifesciences Ltd.
What is Return on Equity (ROE) and why is it important for NECLIFE?
NECLIFE has an ROE of -11.23%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Nectar Lifesciences Ltd generates profits from shareholders' equity.
How is NECLIFE's debt-to-equity ratio and what does it indicate?
NECLIFE has a debt-to-equity ratio of 0.64, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is NECLIFE's dividend yield and is it a good dividend stock?
NECLIFE offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has NECLIFE grown over the past 5 years?
NECLIFE has achieved 5-year growth rates of: Sales Growth -6.77%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in NECLIFE and why does it matter?
Promoters hold 44.90% of NECLIFE shares, with 98.77% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is NECLIFE's market capitalization category?
NECLIFE has a market capitalization of ₹391 crores, placing it in the Small-cap category.
How volatile is NECLIFE stock?
NECLIFE has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for NECLIFE?
NECLIFE has a 52-week high of ₹N/A and low of ₹N/A.
What is NECLIFE's operating profit margin trend?
NECLIFE has a 5-year average Operating Profit Margin (OPM) of 5.49%, indicating the company's operational efficiency.
How is NECLIFE's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -0.52% and YoY Profit Growth of -43.48%.
What is the institutional holding pattern in NECLIFE?
NECLIFE has FII holding of 0.62% and DII holding of 0.08%. Significant institutional holding often suggests professional confidence in the stock.